Belgium's Ablynx in Merck cancer research tie-up: firm

Belgian biotechnology company Ablynx said on Monday it has signed a cancer research cooperation accord with US pharmaceuticals giant Merck & Co. which could be worth up to 1.7 billion euros ($2.3 billion).

The contract, to identify proteins which may lead to cancer immunotherapy treatments, involves an initial payment of 20 million euros plus 10.7 million euros for the three-year research programme.

Subsequent royalties on sales could lead to payment of 1.7 billion euros, Ablynx said in a statement.

Merck will be responsible for development, manufacture and say of any treatments generated by the research.

Immunotherapy treatments aim to boost the body's own immune response so as to fight .

add to favorites email to friend print save as pdf

Related Stories

German drug maker Merck ups forecast for 2013

Nov 14, 2013

German chemicals and pharmaceuticals giant Merck KGaA said Thursday it is raising its full-year operating profit forecast thanks to improving sales and positive cost-cutting effects.

Higher prices for MS drug help drug firm Merck

May 14, 2013

(AP)—Higher prices for its multiple sclerosis drug Rebif helped German pharmaceutical and high-tech materials company Merck KGaA post a 54 percent rise in first-quarter profit.

Recommended for you

Colon cancer rates rising among Americans under 50

6 hours ago

(HealthDay)—Although the overall rate of colon cancer has fallen in recent decades, new research suggests that over the last 20 years the disease has been increasing among young and early middle-aged American ...

The future of precision immunology

10 hours ago

In his State of the Union address, President Obama announced a new precision medicine initiative to work on finding a cure for cancer and other diseases. Howard L. Kaufman, a leading immunotherapy expert ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.